No changes in anti-JCV antibody status after Natalizumab discontinuation in a large population of Multiple Sclerosis patients

被引：0
|
作者：
Sgarlata, E. [1 ,2 ]
Chisari, C. G. [3 ]
D'Amico, E. [3 ]
Toscano, S. [3 ]
Zanghi, A. [3 ]
Lo Fermo, S. [3 ]
Patti, F. [3 ]
机构：
[1] Sapienza Univ, Dept Human Neurosci, Rome, Italy
[2] Umberto I Hosp, Dept Med, Siracusa, Italy
[3] Univ Catania, Sect Neurosci, Dept GF Ingrassia, Catania, Italy
来源：
MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P658
引用
收藏
页码：325 / 325
页数：1
相关论文
共 50 条
  • [1] Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab
    Sgarlata, Eleonora
    Chisari, Clara Grazia
    D'Amico, Emanuele
    Millefiorini, Enrico
    Patti, Francesco
    CNS DRUGS, 2020, 34 (05) : 535 - 543
  • [2] Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab
    Eleonora Sgarlata
    Clara Grazia Chisari
    Emanuele D’Amico
    Enrico Millefiorini
    Francesco Patti
    CNS Drugs, 2020, 34 : 535 - 543
  • [3] Anti-JCV antibody index seroconversion in Turkish multiple sclerosis patients treated with natalizumab
    Edanur Şahin
    Tuncay Gündüz
    Ahmed Serkan Emekli
    Mazlum Ercanoğlu
    Sevda Öztürk Erden
    Murat Kürtüncü
    Neurological Sciences, 2025, 46 (4) : 1799 - 1805
  • [4] Serum Anti-JCV Antibody Status in Western Australian Patients With Multiple Sclerosis
    Fabis-Pedrini, Marzena
    Jeereddy, Shaila
    Carroll, William
    Kermode, Allan
    NEUROLOGY, 2019, 92 (15)
  • [5] Longitudinal Analysis of Anti-JCV Antibody Index in Natalizumab-Treated Multiple Sclerosis Patients
    McGurgan, Iain
    Lockhart, Andrew
    Hutchinson, Michael
    McGuigan, Christopher
    NEUROLOGY, 2016, 86
  • [6] Serum Anti-JCV Antibody Status in Western Australian Patients With Multiple Sclerosis
    Fabis-Pedrini, Marzena J.
    Jeereddy, Shaila
    Carroll, William M.
    Kermode, Allan G.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (03) : 450 - 450
  • [7] Natalizumab efficacy is unaffected by baseline anti-JCV antibody status
    Hotermans, C.
    Subramanyam, M.
    Pace, A.
    Potts, J.
    JOURNAL OF NEUROLOGY, 2011, 258 : 255 - 255
  • [8] Analysis of Anti-JCV antibody in Japanese patients with multiple sclerosis
    Aoyama, S.
    Mori, M.
    Uchida, T.
    Masuda, H.
    Ohtani, R.
    Sugimoto, K.
    Liu, J.
    Kuwabara, S.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 238 - 239
  • [9] Anti-JCV antibody serology is associated with CSF cell counts in multiple sclerosis patients with and without natalizumab treatment
    Schneider-Hohendorf, T.
    Schulte-Mecklenbeck, A.
    Ostkamp, P.
    Luessi, F.
    Klotz, L.
    Zipp, F.
    Wiendl, H.
    Gross, C. C.
    Schwab, N.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 1007 - 1007
  • [10] Should we broaden indications for anti-JCV antibody tests in multiple sclerosis patients? Comments. Anti-JCV antibody index in multiple sclerosis care
    Stankoff, B.
    REVUE NEUROLOGIQUE, 2017, 173 (10) : 616 - 618
12345